![]() rac 4-Hydroxydebrisoquine Hemisulfate structure
|
Common Name | rac 4-Hydroxydebrisoquine Hemisulfate | ||
---|---|---|---|---|
CAS Number | 62580-84-1 | Molecular Weight | 289.30800 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C10H15N3O5S | Melting Point | 262-265ºC | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
![]() GHS07 |
Signal Word | Warning |
Name | 4-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboximidamide,sulfuric acid |
---|---|
Synonym | More Synonyms |
Melting Point | 262-265ºC |
---|---|
Molecular Formula | C10H15N3O5S |
Molecular Weight | 289.30800 |
Exact Mass | 289.07300 |
PSA | 156.32000 |
LogP | 1.59500 |
Symbol |
![]() GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi |
Risk Phrases | 36/37/38 |
Safety Phrases | 26 |
RIDADR | NONH for all modes of transport |
Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate.
Biochem. Pharmacol. 58(3) , 439-45, (1999) The microsomal oxidative transformation of a non-physiological N-hydroxyguanidine was demonstrated for the first time for N-hydroxydebrisoquine as a model substrate (Clement et al., Biochem Pharmacol ... |
|
Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
Br. J. Clin. Pharmacol. 45(3) , 315-7, (1998) To determine the effect of therapeutic loading doses of halofantrine and chloroquine on CYP2D6 activity in healthy black Zambians.Twenty healthy black male Zambians were phenotyped for CYP2D6 activity... |
|
Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Clin. Chem. Lab Med. 43(3) , 275-9, (2005) The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several clinically important drugs. So far more than 50 different CYP2D6 allelic variants have been described... |
( inverted exclamation markA)-3,4-Dihydro-4-hydroxy-2(1H)-isoquinolinecarboximidamide sulfate |
( inverted exclamation markA)-4-Hydroxydebrisoquin sulfate |
( inverted exclamation markA)-2-Amidino-4-hydroxy-1,2,3,4-tetrahydroisoquinoline sulfate |